Estronex
Toda mulher deve saber seu risco para câncer de mama. Agora ela pode com um simples teste de urina!
Quando um grande estudo de terapia de reposição hormonal em mulheres foi recentemente interrompido, médicos e pacientes permaneceram com perguntas não respondidas. Porque certos tecidos, como os das mamas são suscetíveis ao câncer estrogênio-dependente? Porque algumas mulheres são suscetíveis e outras não? Pesquisas da Universidade de Rockefeller revelaram que o corpo metaboliza estrógenos em vários metabólitos diferentes que podem impactar no desenvolvimento do câncer.
Um metabólito, 2-hidroxiestrona (2-OHE1) tende a inibir o crescimento do câncer. Outro, 16-alfa-hidroxiestrona (16-alfa-OHE1), na verdade estimula o desenvolvimento do tumor. As “ïndividualidades bioquímicas” da mulher determinam quais desses metabólitos predominam. Estudos mostram que a razão entre esses dois metabólitos fornece indicacão importante do risco de desenvolvimento do câncer estrogênio-dependente.
Os estudos também mostram que esse risco é modificável.
O Estronex™ 2/16 Teste da Healthmetrix mede a razão entre esses dois metabólitos críticos do estrogênio em uma simples amostra de urina. A razão Estronex™ 2/16 menor que 2.0 indica aumento do risco a longo prazo para câncer de mama, colo uterino e outros estrogênio-dependentes. Felizmente, intervenções nutricionais podem auxiliar no aumento da razão Estronex 2/16 e reduzir o risco a longo prazo.
Referências:
1. Irminger-Finger I. Science of cancer and aging. J Clin Oncol. 2007 May 10;25(14): 1844-51.
2. Simone CB. Cancer and Nutrition. Lawrenceville, NJ: Princeton Institute; 2005.
3. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23;343(21): 1566-8.
4. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 1989 Nov 18;2(8673):1176-8.
5. Garland CF, Garland FC, Gorham ED. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr. 1991 Jul;54(1 Suppl):193S-201S.
6. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11.
7. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94.
8. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphism, and risk of advanced prostate cancer. Cancer Res. 2005 Jun 15;65(12):5470-9.
9. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61.
10. Lappe JM, Traves-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am j Clin Nutr. 2007 Jun;85(6):1586-91.
11. Friedrich M, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003;164:239-46.
12. De Lycra EC, da S, I,Katayama ML, et al. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 2-4-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 2006 Aug; 100(4-5):184-92.
13. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006 Sep;92(1):49-95.
14. Skinner HG, Michaud DS, Giovannucci E, et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95.
15. Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006 May;6(3):229-44.
16. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001 Jan;165(1):253-8.
17. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005 Jun;10(2):94-111.
18. Mernitz H, Smith DE, Wood RJ, Russell RM, Wang XD. Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: evidence of retinoid mitigation of vitamin D toxicity. Int J Cancer. 2007 Apr 1;120(7):1402-9.
19. Becker S, Cordes T, Diesing D, Diedrich K, Friedrich M. Expression of 25 hydroxyvitamin D3- 1 alpha-hydroxylase in human endometrial tissue. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):771-5.
20. Polese J, Talamini R, Montella M, et al. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. Ann Oncol. 2006 Apr;17(4):713-8.
21. Imseis RE, Palmieri GM, Holbert JM, Leventhal MR, Sebes JI. Effect of calcitriol and pamidronate in multiple myeloma. Am J Med Sci. 1999 Jul;318(1):61-6.
22. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81.
23. Zhu G, Zhang YQ, Wan B. Role of dietary factors in prostate cancer development. Zhonghua Nan Ke Xue. 2005 May;11(5):375-8
24. Taylor EF, Burley VJ, Greenwood DC, Cade JE. Meat consumption and risk of breast cancer in the UK Women’s Cohort Study. Br J Cancer. 2007 Apr 10;96(7):1139-46.
25. Cui X, Daí Q, Tseng M et al. Dietary patterns and breast cancer risk in the shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1443-8.
26. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat. 2006, May;97(1):97-106.
27. Tavani A, Giordano L, Gallus S, et al. Consumption of sweet foods and breast cancer risk in Italy. Ann Oncol. 2006 Feb;17(2):341-5.
28. Lajous M, Willert W, Lazcano-Ponce E, et al. Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control. 2005 Dec;16(10):1165-9.
29. Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr. 2004 Jul;80(1):5-14.
30. Brennan P, Hsu CC, Moullan N, et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomization approach. Lancet. 2005 Oct 29;366(9496):1558-60.
31. Ambrosone CB, McCann SE, Freudenheim JL, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004 May;134(5):1134-8.
32. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemilogical evidence. Nutr Cancer. 2002;42(1):1-9.
33. Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res. 1999 Aug 15;59(16):3991-7.
34. Zhang SM, Hunter DJ, Rosner BA, et al. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin’s lymphoma among women.
35. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3’- diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.
36. Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res. 2007 May;635(2-3):90-104.
37. Conaway CC, Wang CX, Pittman B, et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res. 2005 Sep. 15;65(18):8548-57.
38. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human drug metabolizing activity. Cancer Lett. 1997 Mar 19;114(1-2):169-70.
39. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996 Sep; 150 SuppleS259-65.
40. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000 Nov;11(6):635-40.
41. Muti P, Westerlind K, Wu T, et al. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002 Dec;13(10):947-55.
42. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP. Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg. 2001 Mar;124(3):241-7.
43. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):505-9.
44.Kabat GC, O’Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006 Jan;17(1):80-8.
45. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism on healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.
46. Fowke JH, Qi D, Bradlow HJ, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with preversus post-treatment collection. Steroids. 2003 Jan;68(1):65-72.
47. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997 May 21;89(10):718-23.
48. Wong GY, Bradlow L, Sepkovic D, et al. Doseranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl. 1997;28-29:111-6.
49. Hirose K, Tajima K, Hamajima N, et al. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res. 1995 Feb;86(2):146-54.
50. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998 Dec;9(6):553-7.
51. Kurahashi N, Iwasaki M, Sasazuki S, et al. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45.
52. Messina MJ. Legumes ans soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999 Sep;70(3 Suppl):439S-50S.
53. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-913.
54. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone sonsumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8.
55. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA. 2005 Sep 28;294(12):1493-504.
56. Nothilings U, Murphy SP, Wilkens LR, Hernderson BE, Kolonel LN. Flavonols and Pancreatic Cancer Risk: The Multiethnic Cohort Study. Am J Epidemiol. 2007 Aug 9.
57. Xu HS, Dai SL, Sun RY. Cardiovascular effects of phytoestrogens. Zhongguo Yi Xue Ke Xue Yuan Xue Boa. 2005 Apr;27(2):258-61.
58. de Kleijn MJ, van der Schouw YT, Wilson PW, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham study. J Nutr. 2002Feb;132(2):276-82.
59. Roudsari AH, Tahbaz F, Hossein-Nezhad A, et al. Assessment of soy phytoestrigens’effects on bone turnover indicators in menopausal women with osteopenia in Iran: a before and after clinical trial. Nutr J. 2005;430.
60. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13.
61. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 1995 Mar;125(3 Suppl):777S-83S.
62. Setchell KD. Soy isoflavones-benefits and risks from nature’s selective estrogen receptors modulators (SERMs). J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-62S; discussion 381S-383S.
63. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast-cancer risk in Singapore. Lancet. 1991 May 18;337(8751):1197-200.
64. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64.
65. Schroder FH, Roobol MJ, Boever ER, et al. Randomized, double-blind, placebo-controlled crossover sudy in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 Dec;48(6):922-30.
66. Nagata Y, Sonoda T, Mori M, et al. Fujimoto Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007 Aug;137(8):1974-9.
67. Availabe at http://www.cdc.gov/omhd/Highlights/2007/Hjune07.htm#2. Accessed August 10. 2007.
68. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 2004 Mar;95(3):238-42.
69. Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nestes case-control study among Japanese men. Cancer Sc. 2004 Jan;95(1):65-71.
70. Available at http://www.garfield.library.upenn.edu/histcomp/kritchevsky-d_auth-citing/node/7082.html. Accessed August 20, 2007.
71. Dwivedi C, Heck WJ, Downie AA, Larroya S, Webb TE. Effect of calcium and glucarate content of certain vegetables e frutas. Biochem Med Metab Biol. 1990 Apr;43(2):83-92.
72. Walaszek Z, Szemraj J, Narog M et al. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potencial use in cancer prevention. Cancer Detect Prev. 1997;21(2):178-90.
73. No authors listed. Calcium-D-glucarate. Altern Med Rev. 2002 Aug;7(4):336-9.
74. Walaszek Z, Hanausek M, Sherman U, Adams AK. Antiproliferative effect of dietary glucarate on the Sprague-Dawley rat mammary gland. Cancer Lett. 1990 Jan;49(1):57-1.
75. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. Isr J Med Sci. 1995 Feb;31(2-3):101-5.
76. Slaga TJ, Quilici-Timmcke J. D-Glucarate: A Nutrient Against Cancer. Columbus, Ohio: McGraw-Hill; 1999.
77. Walszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Carcinogenesis. 1986 Sep;7(9):1463-6.
78. Abou-Issa H, Moeschnerger M, el-Masry W, et al. Relative efficacy of glucarate on the initiation and promotion phases of rat mammart carcinogenesis. Anticancer Res. 1995 May;15(3):805-10.
79. Magnúsdóttir EV. Phytoestrogens and human health. Laeknabladid. 2002 Nov;88(11):821-5.
80. McCann SE, Muti P, Vito D, et al. Dietary lignan intakes and risk of pre-and postmenopausal breast cancer. Int J Cancer . 2004 Seo1;111(3):440-3.
81. Boccardo F, Lunardi G, Guglielmini P, et al. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur J Cancer. 2004 Jan;40(1):84-9.
82. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-beyond physical activity. Cancer Res. 1997 Jan 1;57(1):75-80.
83. Michels KB. The role of nutrition in cancer development and prevention. Int J Cancer. 2005 Mar 20;114(2):163-5.
84. Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol. 2007 Aug;110(2 Pt 1 ):230-40.
85. Von Bamberger CM. Prevention and anti-aging in endocrinology. MMW Fortschr Med. 2007 Mar 1;149(9):33-5.
86. Izumi S, Tsubahara A. Improvement of peripheral neuropathy by testosterone in a patient with 48, XXYY syndrome. Tokai J Exp Clin Med. 2000 Jun;25(2);39-44.
87. Phillips GB, Pinkernell BH, Jing TY. The association oh hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994 May;14(5):701-6.
88. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endigenous androgens increase the risk of atherosclerosis in elderly men: the Rottherdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.
89. Pope HG, Jr., Cohane GH, Kanayama supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105-11.
90. Zumoff B. Hormonal abnormalities in obesity. Acta Med Scand Suppl. 1988;723:153-60.
91. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002 Jun;5(2);98-102.
92. Novák A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas. 2002 Dec 10;43(4):231-7.
93. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann NY Acad Sci. 1995 Sep 30;768:180-200.
94. Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Clin North Am. 1994 Dec;21(4);751-72.
95. Napoli N, Armamento-Villareal R. Estrogen hydroxylation in osteoporosis. Adv Clin Chem. 2007;43:211-27.
96. Bradlow HL, Telang NT, Sepkovic DW, Osbourne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996 Sep;150 Suppl: S259-65.